Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G
Cattedra di Gastroenterologia, Azienda Ospedaliera "L Sacco", Polo Universitario, Via G.B. Grassi 74, 20157 Milano, Italy.
Gut. 2006 Jan;55(1):47-53. doi: 10.1136/gut.2005.068809. Epub 2005 Jun 21.
There are limited evidence based data concerning the use of azathioprine in ulcerative colitis. We aimed to compare the efficacy of azathioprine and oral 5-aminosalicylic acid in inducing remission of steroid dependent ulcerative colitis.
Seventy two patients with steroid dependent ulcerative colitis were admitted to this investigator-blind study. Steroid dependence was defined as a requirement for steroid therapy > or =10 mg/day during the preceding six months, with at least two attempts to discontinue the medication. The disease had to be clinically and endoscopically active at study entry, and all patients were taking systemic prednisolone (40 mg/day). Patients were randomised to receive azathioprine 2 mg/kg/day or oral 5-aminosalicylic acid 3.2 g/day, for a six month follow up period. The outcome of the treatment was defined as (1) success, indicating induction of clinical and endoscopic remission and steroid discontinuation, or (2) failure, indicating the absence of clinical and endoscopic remission and therefore the need for at least one further cycle of systemic steroids to control symptoms, apart from the initial one, or colectomy.
Significantly more patients in the azathioprine than in the 5-aminosalicylic acid group had clinical and endoscopic remission, and discontinued steroid therapy, both in the intention to treat (azathioprine v 5-aminosalicylic acid: 19/36 patients (53%) v 7/36 (21%); odds ratio (OR) 4.78 (95% confidence interval (CI) 1.57-14.5)) and per protocol (azathioprine v 5-aminosalicylic acid: 19/33 patients (58%) v 7/34 (21%); OR 5.26 (95% CI 1.59-18.1)) analysis.
Azathioprine is significantly more effective than 5-aminosalicylic acid in inducing clinical and endoscopic remission and avoiding steroid requirement in the treatment of steroid dependent ulcerative colitis.
关于硫唑嘌呤在溃疡性结肠炎中的应用,基于证据的数据有限。我们旨在比较硫唑嘌呤和口服5-氨基水杨酸诱导激素依赖型溃疡性结肠炎缓解的疗效。
72例激素依赖型溃疡性结肠炎患者被纳入这项研究者设盲的研究。激素依赖定义为在过去6个月内需要≥10mg/天的激素治疗,且至少有两次尝试停药。在研究开始时,疾病必须在临床和内镜下处于活动期,所有患者均服用系统性泼尼松龙(40mg/天)。患者被随机分为接受2mg/kg/天硫唑嘌呤或3.2g/天口服5-氨基水杨酸治疗,随访6个月。治疗结果定义为:(1)成功,即诱导临床和内镜缓解并停用激素;(2)失败,即未出现临床和内镜缓解,因此除初始疗程外,需要至少一个额外的系统性激素疗程来控制症状,或进行结肠切除术。
在意向性分析(硫唑嘌呤组与5-氨基水杨酸组:19/36例患者(53%)对7/36例(21%);优势比(OR)4.78(95%置信区间(CI)1.57 - 14.5))和符合方案分析(硫唑嘌呤组与5-氨基水杨酸组:19/33例患者(58%)对7/34例(21%);OR 5.26(95%CI 1.59 - 18.1))中,硫唑嘌呤组临床和内镜缓解且停用激素的患者显著多于5-氨基水杨酸组。
在激素依赖型溃疡性结肠炎治疗中,硫唑嘌呤在诱导临床和内镜缓解以及避免激素需求方面显著优于5-氨基水杨酸。